BioVie and BioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie and BioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
RedChip公司將在Bloomberg電視上贊助的節目《RedChip節目》於東部時間7月6日星期六晚7點播出BioVie, Inc. (納斯達克:BIVI)和bioAffinity Technologies, Inc. (納斯達克:BIAF)的採訪。Bloomberg TV 可通過大約7300萬美國家庭觀看。小公司股票、大鈔票bioAffinity Technologies:
Access the interviews in their entirety at:
Soligenix:
BioVie:
bioAffinity Technologies:
BioVie：
bioAffinity Technologies的總裁兼首席執行官Maria Zannes將在Bloomberg TV的RedChip節目上提供公司更新。bioAffinity Technologies是早期癌症診斷領域的新興參與者。其旗艦產品CyPath Lung通過分析肺部微環境提高早期肺癌的檢測效率。這種非侵入性的測試具有高靈敏度、特異性和準確性。肺癌往往在達到晚期時才被發現，治療方案的效果不佳。早期檢測可提高生存率並降低醫療費用。隨着商業化計劃的推廣，包括德克薩斯州的試點計劃和美國國防部爲進行持續性研究而購買測試，公司已爲創業板做好了準備。到2030年，肺癌篩查市場預計將達到57億美元。公司正在開發由人工智能驅動的自動化數據分析來協助非侵入性診斷慢性阻塞性肺疾病和哮喘的細胞流式分析平台，這兩種疾病的全球市場預計將在2027年達到82億美元。公司擁有廣泛的美國和國際專利。內部人士對公司的持股力度非常強，持股比例爲39%並且持續增加。擁有高度經驗的領導團隊，bioAffinity Technologies在早期癌症診斷領域具備推動創新的優勢。
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
在一次獨家採訪中，BioVie的總裁兼首席執行官Cuong Do將分享有關公司針對神經退行性和肝病等未滿足醫學需求的晚期臨床項目管道的見解。BioVie的主要資產bezisterim（前NE3107）已經證明其調節TNFα的產生能力，從而帶來了重大的臨床改善。接受bezisterim治療的患者經歷了氣體降低和胰島素抵抗，改善了帕金森氏症（PD）運動控制和“晨起症狀”，提高了認知和功能，並在阿爾茨海默病（AD）方面改善了腦成像掃描，以及降低了DNA的甲基化水平。該公司的戰略重點包括在2024年秋季啓動針對帕金森病的二期試驗，在2025年中期啓動使用新的一天一次的製劑的阿爾茨海默病三期試驗bezisterim，持續尋找bezisterim地理權益的合作伙伴，並在確定合適的合作伙伴後啓動一項腹水三期試驗。
Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. bioAffinity Technologies is an emerging player in early-stage cancer diagnosis. Its flagship product, CyPath Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD's purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Company's flow cytometry platform, enhanced by AI-driven automated data analysis, is being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach $8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the Company with ownership at 39% and increasing. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis.
bioAffinity Technologies的總裁兼首席執行官Maria Zannes將在Bloomberg電視臺的RedChip節目上亮相，提供公司更新。小公司股票、大鈔票bioAffinity Technologies是早期癌症診斷領域的新興參與者。其旗艦產品CyPath Lung通過分析肺部微環境提高早期肺癌的檢測效率。這種非侵入性的測試具有高靈敏度、特異性和準確性。肺癌往往在達到晚期時才被發現，治療方案的效果不佳。早期檢測可提高生存率並降低醫療費用。隨着商業化計劃的推廣，包括德克薩斯州的試點計劃和美國國防部爲進行持續性研究而購買測試，公司已爲創業板做好了準備。到2030年，肺癌篩查市場預計將達到57億美元。公司正在開發由人工智能驅動的自動化數據分析來協助非侵入性診斷慢性阻塞性肺疾病和哮喘的細胞流式分析平台，這兩種疾病的全球市場預計將在2027年達到82億美元。公司擁有廣泛的美國和國際專利。內部人士對公司的持股力度非常強，持股比例爲39%並且持續增加。擁有高度經驗的領導團隊，bioAffinity Technologies在早期癌症診斷領域具備推動創新的優勢。
About BioVie Inc.
BioVie股份有限公司（NASDAQ：BIVI）是一家臨床階段公司，致力於開發治療神經系統和神經退行性疾病以及先進肝病的創新藥物療法。
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit .
BioVie Inc. (NASDAQ: BIVI)是一家國內處於臨床階段的公司，致力於研發針對神經和神經退行性疾病以及先進肝病的創新藥物療法。在神經退行性疾病中，公司的藥物候選bezisterim抑制ERK和NFκB（例如，TNF信號轉導）的炎症活化，導致神經炎症和胰島素抵抗，但不影響它們的穩態功能（例如，胰島素信號轉導和神經元生長和存活）。都是阿爾茨海默病（AD）和帕金森氏症（PD）的驅動因素。在肝病方面，公司的孤兒藥物候選BIV201（連續輸注替利福汀），經美國食品和藥品管理局（“FDA”）加速審批，正在評估中，並已收到FDA關於對由慢性肝硬化引起的腹水進行BIV201三期臨床測試設計的指導。這種活性物質在美國和大約40個國家中被批准用於治療晚期肝硬化的相關併發症。有關更多信息，請訪問。
About bioAffinity Technologies, Inc.
關於bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPathLung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPathLung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit and follow us on LinkedIn, Facebook and X.
bioAffinity Technologies, Inc.致力於非侵入性診斷早期癌症和肺部疾病以及廣譜抗癌治療的需要。該公司的第一個產品CyPath Lung是一種非侵入性的測試，已經顯示出檢測早期肺癌的高靈敏度、特異性和準確性。CyPath Lung是BioAffinity Technologies子公司Precision Pathology實驗室開發的一種實驗室開發的測試。公司在Precision Pathology和The University of Texas at San Antonio的實驗室中開展了平台技術的研究和優化。欲了解更多信息，請登陸官方網站，並在LinkedIn、Facebook和X上關注我們。Lung是一種非侵入性的測試，已經顯示出檢測早期肺癌的高靈敏度、特異性和準確性。CyPath Lung是由BioAffinity Technologies子公司Precision Pathology實驗室開發的一種實驗室開發的測試。
About RedChip Companies
關於RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip公司是一家國際投資者關係、媒體和研究公司，是一家美國《Inc.》雜誌5000強公司，專注於微型市值和小市值公司。32年來，RedChip爲客戶提供了具體、可衡量的成果。我們的新聞簡報，“小公司股票、大鈔票”，每週在線上向6萬投資者發送。RedChip已經開發出行業中最全面的服務平台，爲微型市值和小市值公司提供以下服務：股票研究的全球分銷網絡；在美國主要城市進行散戶和機構路演；外發營銷給股票經紀人、RIA、機構和家族辦公室；數字媒體投資者關係平台，爲股東帶來數百萬次獨特的投資者瀏覽量；投資者網絡研討會和集體電話；電視節目，“小公司股票、大鈔票”，每週在Bloomberg US播出；在地方和全國市場上的電視廣告；公司和產品視頻；網站設計；傳統投資者關係服務，包括新聞稿撰寫、投資者演示文稿的製作、季度電話會議劇本的編寫、戰略諮詢、融資等。小公司股票、大鈔票在線向6萬投資者每週發送的電子郵件新聞簡報，“小公司股票、大鈔票”小公司股票、大鈔票在Bloomberg US每週播出的電視節目“小公司股票、大鈔票”
To learn more about RedChip's products and services, please visit:
要了解更多有關RedChip的產品和服務的信息，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“發現明日的藍籌股”
Follow RedChip on LinkedIn:
在LinkedIn上關注RedChip：
Follow RedChip on Facebook:
在Facebook上關注RedChip：
Follow RedChip on Instagram:
在Instagram上關注RedChip：
Follow RedChip on Twitter:
在Twitter上關注RedChip：
Follow RedChip on YouTube:
在YouTube上關注RedChip：
Follow RedChip on Rumble:
在Rumble上關注RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
來源：RedChip